HNGEHinge Health, Inc.
Is the price fair?
Priced for a lot of growth. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~11% a year FCF growth. The price already bakes in strong, sustained growth.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What HNGE's price assumes
Hinge Health, Inc. has no trailing P/E on file, so the price is measured against sales instead: 9.62× revenue.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 3.2%
Free cash flow yield · Health Information Services median 4.5%
- Growth the price implies
- +11%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- Price / book
- 20.1
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 20.1
- Free cash flow, trailing twelve months
- $290M
- Market capitalisation80.7 million shares, counted Jul 29, 2026
- $8.98B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Health Information Services
The closest names by size in the same industry